Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
Plus Therapeutics (Nasdaq: PSTV) will present new data on its Leptomeningeal Metastases (LM) programs at the 2024 SNO/ASCO CNS Metastases Conference. The company will host a symposium on 'Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases' on August 8. Key presentations include:
1. Phase 1 dose escalation study of Rhenium (186Re) Obisbemeda for LM treatment
2. Radiation absorbed dose to spinal cord in LM therapy using beta-emission radiopharmaceuticals
3. CSF Tumor Cell detection for clinical management of breast and lung cancer patients with LM
4. CNSide CSF Tumor Cell detection platform for LM disease management
These presentations highlight Plus Therapeutics' progress in both therapeutic and diagnostic approaches for LM, a challenging area in central nervous system cancers.
Plus Therapeutics (Nasdaq: PSTV) presenterà nuovi dati sui suoi programmi per le Metastasi Leptomeningeali (LM) durante la Conferenza SNO/ASCO sulle Metastasi CNS del 2024. L'azienda ospiterà un simposio su 'Nuovi approcci diagnostici e terapeutici emergenti per le Metastasi Leptomeningeali' l'8 agosto. Le presentazioni chiave includono:
1. Studio di fase 1 sull'escalation della dose di Rhenium (186Re) Obisbemeda per il trattamento delle LM.
2. Dose assorbita di radiazione al midollo spinale nella terapia per le LM utilizzando radiopharmaceuticals ad emissione beta.
3. Rilevazione di cellule tumorali nel liquido cerebrospinale per la gestione clinica dei pazienti con cancro al seno e ai polmoni con LM.
4. Piattaforma di rilevamento delle cellule tumorali nel liquido cerebrospinale CNSide per la gestione della malattia LM.
Queste presentazioni evidenziano i progressi di Plus Therapeutics sia negli approcci terapeutici che diagnostici per le LM, un'area sfidante nei tumori del sistema nervoso centrale.
Plus Therapeutics (Nasdaq: PSTV) presentará nuevos datos sobre sus programas de Metástasis Leptomeníngeas (LM) en la Conferencia sobre Metástasis CNS SNO/ASCO 2024. La empresa organizará un simposio sobre 'Nuevos enfoques diagnósticos y terapéuticos emergentes para las Metástasis Leptomeníngeas' el 8 de agosto. Las presentaciones clave incluyen:
1. Estudio de fase 1 de escalada de dosis de Rhenium (186Re) Obisbemeda para el tratamiento de LM.
2. Dosis de radiación absorbida en la médula espinal en terapia de LM utilizando radiopharmaceuticals de emisión beta.
3. Detección de células tumorales en líquido cefalorraquídeo para la gestión clínica de pacientes con cáncer de mama y pulmón con LM.
4. Plataforma de detección de células tumorales en líquido cefalorraquídeo CNSide para la gestión de la enfermedad LM.
Estas presentaciones destacan el progreso de Plus Therapeutics tanto en enfoques terapéuticos como diagnósticos para LM, un área desafiante en los cánceres del sistema nervioso central.
플러스 테라퓨틱스(상장코드: PSTV)는 2024 SNO/ASCO CNS 전이 회의에서 수막 전이(LM) 프로그램에 대한 새로운 데이터를 발표할 예정입니다. 회사는 8월 8일 '수막 전이에 대한 새로운 진단 및 치료 접근법'이라는 주제로 심포지엄을 개최합니다. 주요 발표 내용은 다음과 같습니다:
1. LM 치료를 위한 레늄(186Re) 오비스베메다의 1상 용량 증가 연구
2. 베타 방사선 의약품을 이용한 LM 치료에서 척수에 대한 방사선 흡수 용량
3. LM 환자를 위한 유방암 및 폐암 클리닉 관리에서의 CSF 종양 세포 검출
4. LM 질병 관리를 위한 CNSide CSF 종양 세포 검출 플랫폼
이 발표들은 중앙 신경계 암의 도전적인 분야인 LM에 대한 치료 및 진단 접근법에서 Plus Therapeutics의 진전을 강조합니다.
Plus Therapeutics (Nasdaq: PSTV) présentera de nouvelles données concernant ses programmes sur les métastases leptomeningeales (LM) lors de la conférence SNO/ASCO sur les métastases du SNC en 2024. L'entreprise organisera un symposium sur 'Nouveaux approches diagnostiques et thérapeutiques émergentes pour les métastases leptomeningeales' le 8 août. Les présentations clés incluent :
1. Étude de phase 1 sur l'escalade de dosage de Rhenium (186Re) Obisbemeda pour le traitement des LM.
2. Dose de radiation absorbée au niveau de la moelle épinière dans les thérapies LM utilisant des radiopharmaceutiques à émission beta.
3. Détection des cellules tumorales dans le liquide céphalorachidien pour la gestion clinique des patients atteints de cancer du sein et du poumon ayant des LM.
4. Plateforme de détection des cellules tumorales dans le liquide céphalorachidien CNSide pour la gestion de la maladie LM.
Ces présentations mettent en évidence les progrès de Plus Therapeutics tant dans les approches thérapeutiques que diagnostiques concernant les LM, un domaine difficile des cancers du système nerveux central.
Plus Therapeutics (Nasdaq: PSTV) wird neue Daten zu seinen Programmen für leptomeningeale Metastasen (LM) auf der SNO/ASCO CNS Metastasen-Konferenz 2024 präsentieren. Das Unternehmen wird am 8. August ein Symposium mit dem Thema 'Aufkommende neuartige diagnostische und therapeutische Ansätze für leptomeningeale Metastasen' veranstalten. Zu den wichtigen Präsentationen gehören:
1. Phase-1-Dosis-Eskalationsstudie von Rhenium (186Re) Obisbemeda zur Behandlung von LM.
2. Strahlendosisabsorption im Rückenmark bei LM-Therapien mit Beta-Emissions-Radiopharmazeutika.
3. Nachweis von Tumorzellen im Liquor cerebrospinalis zur klinischen Betreuung von Brust- und Lungenkrebspatienten mit LM.
4. CNSide-Plattform zum Nachweis von Tumorzellen im Liquor cerebrospinalis für das Management von LM-Krankheiten.
Diese Präsentationen heben den Fortschritt von Plus Therapeutics sowohl in therapeutischen als auch in diagnostischen Ansätzen für LM hervor, einem herausfordernden Bereich bei Tumoren des zentralen Nervensystems.
- Multiple presentations at a major conference (SNO/ASCO) showcasing the company's LM programs
- Hosting a symposium with key opinion leaders in the field
- Advancing both therapeutic and diagnostic approaches for Leptomeningeal Metastases
- None.
Company to present new data, highlighting progress in its therapeutics and diagnostics programs for Leptomeningeal Metastases
AUSTIN, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the 2024 Society for Neuro-Oncology (SNO) / American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, in Denver, Colorado.
“This year’s SNO/ASCO Metastases conference is a key opportunity for Plus to highlight advancements in our LM therapeutics and diagnostics programs,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “The conference gathers key influencers and clinicians to discuss important topics in the field and we are honored to have multiple opportunities to share our results with the scientific community.”
Events and data presentations include:
Symposium:
The Company will be hosting a symposium titled, “Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases” on August 8, 2024, at 6:15-7:15 p.m. MDT in the Plaza Ballroom (DEF) of the Sheraton Denver Downtown Hotel. Speakers include:
- Greg Fuller, M.D., Ph.D., Plus Therapeutics Medical Director and VP of Medical Affairs; Former Chief, Section of Neuropathology, The University of Texas MD Anderson Cancer Center
- Seema Nagpal, M.D., Clinical Professor, Neurology & Neurological Sciences, Stanford University
- Jonathan Yang, M.D., Ph.D., Associate Vice Chair for Clinical Research and Developmental Therapeutics, Department of Radiation Oncology, Director of Clinical Research, NYU Langone Health’s Perlmutter Cancer Center
- Andrew Brenner, M.D., Ph.D., Professor and Kolitz / Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, Science Center at San Antonio
Therapeutic:
Presentation:
Title | Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome,186RNL) for the Treatment of Leptomeningeal Metastases (LM): Ongoing Clinical Study Update for Initial Safety and Feasibility), OCTS-11 |
Presenter | Andrew Brenner, M.D., Ph.D. |
Date/Time | Friday, 09 August 2024, 1:10-2:30 p.m. MDT |
Location | Plaza Ballroom (ABC) |
Poster:
Title | Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastases Using Beta-Emission Radiopharmaceuticals, RMTD-08 |
Presenter | Ande Bao, Ph.D., M.S., Assistant Professor, Department of Radiation Oncology, School of Medicine at Case Western University |
Date/Time | Thursday, 08 August 2024, 7:15-09:00 p.m. MDT |
Location | Plaza Exhibit Hall |
Diagnostic:
Presentation:
Title | CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker assessment helps in clinical management of breast cancer and Non-Small Cell Lung cancer patients having Leptomeningeal Disease (FORESEE Study, NCT05414123), BMRK-13 |
Presenter | Priya Kumthekar, M.D., Associate Professor of Neurology and Hematology/Oncology, Northwestern University Medical School |
Date/Time | Saturday, 10 August 2024, 08:45-10:05 a.m. MDT |
Location | Plaza Ballroom (ABC) |
Poster:
Title | The CNSide CSF Tumor Cell detection platform is a feasible, clinically relevant and scalable platform for disease management for patients with Leptomeningeal Disease, BMRK-12 |
Presenter | Arushi Tripathy, M.D., Neurosurgery PGY-4 Resident at University of Michigan Medical School |
Date/Time | Thursday, 08 August 2024, 7:15-9:00 p.m. MDT |
Location | Plaza Exhibit Hall |
About Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3
About Rhenium (186Re) obisbemeda
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
About CNSide Test
CNSide is a laboratory developed test (LDT) based on proprietary quantitative tumor cell capture and detection method, paired with assays to identify actionable molecular treatment targets. Given the genetic changes that can occur as metastatic cancer spreads to the CNS, the evaluation of cerebrospinal fluid with CNSide provides a unique opportunity to identify biomarkers in patients with metastatic carcinoma or melanoma to help guide physicians in therapy selection. In addition, the quantitative tumor cell count assay is designed to be used in a serial fashion to monitor the response to therapy more effectively than other current methods.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of rhenium (186Re) obisbemeda including the ability of rhenium (186Re) obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC and increase of ten o, clinical trials; possible negative effects of rhenium (186Re) obisbemeda; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts; development and utility of CNSide leptomeningeal metastases diagnostic test; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com
![](https://ml.globenewswire.com/media/NGU5ZDBlYmYtZjZhMS00MzAzLTk1YzctMWMwNmYwNjI0NjIyLTEwMTYzNzg=/tiny/Plus-Therapeutics-Inc-.png)
FAQ
What is Plus Therapeutics presenting at the 2024 SNO/ASCO Conference?
When and where is Plus Therapeutics (PSTV) hosting its symposium at the 2024 SNO/ASCO Conference?
What are the key areas of focus for Plus Therapeutics (PSTV) at the 2024 SNO/ASCO Conference?